Stocks in play: Oncolytics Biotech Inc

Provided an enrollment update on the phase 1/2 GOBLET study in a presentation at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The GOBLET study is being managed by AIO, a leading academic cooperative medical oncology group based in Germany, and is designed to evaluate the safety and efficacy of pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab in patients with metastatic pancreatic, metastatic colorectal, and advanced anal cancers. The study includes three-patient safety run-ins for first-line metastatic pancreatic and third-line metastatic colorectal cancer. The study remains ongoing and is expected to enroll patients at 14 clinical trial sites across Germany. Oncolytics Biotech Inc shares T.ONC are trading up $0.15 at $2.28.

Read:

• Wave of Massive ESG Investments Triggering Major Developments in Mining of Critical Minerals

• Investment in New Plant-Based Alternative Meat Products Ramps Up Into 2022

• New Treatments Needed as Breast Cancer Was Leading Killer of Female Cancer Patients in 2019

• Biotech Sector Answering Calls for New Breast Cancer Treatment Developments in 2022

• Alternative Domestic Supplies of Critical Minerals Needed to Facilitate Energy Transition